The evolutionarily conserved target of rapamycin complex 1 (TORC1) is a master regulator of cell growth and metabolism. In mammals, growth factors and cellular energy stimulate mTORC1 activity through inhibition of the TSC complex (TSC1-TSC2-TBC1D7), a negative regulator of mTORC1. Amino acids signal to mTORC1 independently of the TSC complex. Here, we review recently identified regulators that link amino acid sufficiency to mTORC1 activity and how mutations affecting these regulators cause human disease.
Introduction
Nutrients, growth factors and cellular energy trigger synthesis of essential building blocks, such as proteins, lipids, and nucleotides, and thereby stimulate growth. Target of rapamycin complex 1 (TORC1) integrates the above three inputs to activate the metabolic pathways that ultimately drive cell and organismal growth (reviewed in [1] [2] [3] [4] [5] [6] [7] [8] ). Mammalian TORC1 (mTORC1) activity is often deregulated in pathophysiological conditions such as diabetes and cancer (reviewed in [9] ). mTORC1 consists of mTOR, regulatory associated protein of mTOR (RAPTOR), and mammalian lethal with SEC13 protein 8 (mLST8) [10] [11] [12] , and is acutely sensitive to the macrolide rapamycin. Growth factors and cellular energy control mTORC1 via a heterotrimeric TSC complex consisting of tuberous sclerosis complex 1 (TSC1), TSC2, and TRE2-BUB2-CDC16 domain family member 7 (TBC1D7) [13] [14] [15] [16] [17] [18] (Figure 1 ). Binding of growth factors such as insulin to receptor tyrosine kinases (RTKs) activates phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) to generate phosphoinositide 3, 4, 5-phosphate (PIP 3 ). PIP 3 recruits phosphoinositide-dependent kinase 1 (PDK1) and AKT to the plasma membrane via plekstrin homology (PH) domains in these kinases (reviewed in [19] ). PDK1 phosphorylates the activation loop (Thr308) in AKT and thereby activates AKT [20, 21] . AKT phosphorylates TSC2 to inhibit the TSC complex by inducing its release from the lysosome [22] [23] [24] . The TSC complex is a GTPase-activating protein (GAP) toward the lysosomal, small GTPase RAS homologue enriched in brain (RHEB). GTP-loaded RHEB activates mTORC1 via direct interaction with the mTOR catalytic domain [25] , but the precise mechanism of mTORC1 activation by RHEB awaits structural analysis of mTORC1 in complex with RHEB. A high AMP/ATP ratio (low cellular energy) activates AMP-dependent kinase (AMPK) to phosphorylate TSC2, at sites distinct from AKT target sites, and to stimulate GAP activity of the TSC complex [26] . In contrast to growth factors and energy, nutrients (in particular amino acids) activate mTORC1 via a mechanism independent of the TSC complex. Amino acids also stimulate TORC1 activity in the yeast Saccharomyces cerevisiae that lacks a TSC complex. Unlike the insulin-AKT-TSC pathway, the amino acid-sensing branch of TORC1 is evolutionarily conserved from yeast to human. As described below, this branch consists of signaling through RAG GTPases. mTORC1 phosphorylates ribosomal protein S6 kinase (S6K) and eukaryotic translation initiation factor 4E-binding protein (4E-BP) to promote anabolic processes such as protein, lipid, and nucleotide synthesis, and unc-51 like autophagy activating kinase 1 (ULK1) to inhibit autophagy, leading to cell growth. Furthermore, mTORC1 and S6K phosphorylate growth factor receptor-bound protein 10 (GRB10) and insulin receptor substrate 1 (IRS1), respectively [27] [28] [29] . Phosphorylation of GRB10 and IRS1 inhibits PI3K activation, thus forming a negative feedback loop that has an important role in the regulation of growth factor signaling [27] [28] [29] .
Biochemical and genetic studies have identified upstream regulators of mTORC1 in the amino acid-sensing npg www.cell-research.com | Cell Research phorylation of mTORC1 targets S6K and 4E-BP decreases after withdrawal of amino acids, especially leucine, and that insulin fails to stimulate S6K and 4E-BP phosphorylation in the absence of amino acids. These findings suggest that amino acids and insulin act on mTORC1 via distinct mechanisms, both of which are necessary to activate mTORC1. In contrast to the growth factor-sensing insulin-PI3K-AKT pathway, components of the amino acid-sensing branch of mTORC1 were revealed only recently. A first hint came from a genome-wide screen in yeast [31] . Dubouloz et al. [31] reported that the RAG super family member Gtr2, which forms the EGO complex with Ego1, Ego2, and Ego3 [32] , is required for exit from rapamycin-induced growth arrest. In addition, cells deficient for TORC1 activity (tor1∆) are synthetically sick upon deletion of GTR2, indicating a genetic interaction between TOR1 and GTR2. However, this study did not investigate the role of Gtr2 or the EGO complex in the context of a nutrient-sensing pathway. In 2008, two independent groups identified RAG small GTPases as essential components in an amino acid-sensing pathway upstream of TORC1 in flies and mammalian cells [33, 34] (Figure 1 ). Sancak et al. [34] biochemically purified RAPTOR and analyzed associated proteins by mass spectrometry (MS). Kim et al. [33] screened small GTPases in insect cells to identify components of an amino acid-sensing pathway upstream of TORC1. In mammals, there are four RAGs [35] [36] [37] . The highly homologous RAGA or RAGB forms a heterodimer with RAGC or RAGD. Amino acids convert the RAG heterodimer to its active conformation in which RAGA or RAGB is loaded with GTP (RAGA/B-GTP) and RAGC or RAGD is loaded with GDP (RAGC/D-GDP). Sancak et al. [34] further demonstrated that the active RAG heterodimer binds RAPTOR without affecting mTORC1 kinase activity. Instead, the active RAG heterodimer recruits mTORC1 to the surface of the lysosome where RHEB binds and activates mTORC1. In the absence of amino acids, mTORC1 is dispersed in the cytoplasm. It is unclear whether dispersed mTORC1 binds to vesicles or exists as a free complex. Importantly, Sancak et al. [34] answered the long-standing question of why neither amino acids nor growth factors alone are sufficient to activate mTORC1 [30, 38] . Shortly thereafter, Binda et al. [39] showed that the RAG family proteins in yeast, Gtr1 and Gtr2, are also activators of TORC1 in response to leucine ( Figure 2 ). Gtr1 is an ortholog of RAGA and RAGB whereas Gtr2 is an ortholog of RAGC and RAGD [36, 40] . Like RAG proteins in flies and mammals, Gtr1 and Grt2 form a heterodimer complex in which the active conformation is Gtr1-GTP in complex with Gtr2-GDP. Leucine promotes the loading of relevant guanine nucleotides on Gtrs and thereby facilitates a direct physical interaction between TORC1 and the Gtr heterodimer. More recently, Valbuena et al. [41] demonstrated that Gtr1 and Gtr2 are upstream regulators of TORC1 in fission yeast. In contrast to mammals, TORC1 in yeast is localized to the vacuole (yeast equivalent of the lysosome) regardless of leucine availability or guanine nucleotide status of the Gtr proteins. It is unclear how the Gtr heterodimer activates TORC1 or how TORC1 is localized to the vacuole in yeast.
Demetriades et al. [42] demonstrated that amino acid starvation in the presence of growth factors leads to "inactive" RAGs that in turn bind and recruit the TSC complex to the lysosome to inhibit RHEB and thereby TORC1. However, Menon et al. [24] demonstrated that lysosomal translocation of the TSC complex is sensitive to growth factors, and not to amino acids. The reason for this discrepancy is unknown.
RAGULATOR, a GEF for RAGA/B
RAG proteins localize to the lysosomal surface in an amino acid-independent manner, although they do not possess a transmembrane domain or a motif predicted to be lipid-modified. This suggests that another lysosomal protein is involved in the lysosomal localization of the RAGs and mTORC1. Following a biochemical approach similar to the one that identified the RAGs, two studies identified a protein complex consisting of p18 (later renamed LAMTOR1), p14 (LAMTOR2), MP1 (LAM-TOR3), C7orf59 (LAMTOR4), and HBXIP (LAMTOR5), thereafter known as the RAGULATOR complex [38, 43] . Like the RAGs, the RAGULATOR complex localizes to the lysosome in an amino acid-independent manner. Knockdown of any of the components of the RAGU-LATOR complex abrogates lysosomal localization of the RAGs and mTORC1 as well as mTORC1 activity. Importantly, LAMTOR1 is both myristoylated and palmitoylated, and these lipid modifications are required for LAMTOR2 and LAMTOR3 localization to the lysosome [44] . Thus, the RAGULATOR complex serves as a docking site for RAGs and mTORC1 on the lysosome.
RAGs are small GTPases whose ability to regulate TORC1 depends on their GTP-or GDP-loading status. Importantly, amino acids control the guanine nucleotide status of RAGs. In general, exchange of GDP for GTP in a small GTPase is promoted by a guanine nucleotide exchange factor (GEF). Conversely, small GTPases have weak intrinsic GTP hydrolysis activity, and thus conversion of GTP to GDP requires a GTPase-activating protein (GAP). Bar-Peled et al. [43] demonstrated that the pentameric RAGULATOR complex, but not any single subunit, possesses GEF activity toward RAGA and RAGB, and possibly toward RAGC. It is unknown which subunit(s) in RAGULATOR has GEF activity. As discussed in the study of Bar-Peled et al. [43] , the entire pentameric complex might be required for GEF activity. Structural analysis of RAGULATOR may identify the GEF site in the pentameric complex. A structural analysis might also explain the stronger GEF activity toward RAGA/B versus RAGC/D.
Although there is no RAGULATOR ortholog in yeast based on primary sequence, a recent study revealed Figure 2 Regulation of TORC1 in yeast. Yeast TORC1 localizes to the vacuolar surface. The yeast vacuole is equivalent to the mammalian lysosome. Gtr1 and Gtr2 are orthologs of RAGA/B and RAGC/D, respectively. Like RAGs, Gtr1 and Gtr2 form a heterodimer, of which the active conformation is Gtr1-GTP and Gtr2-GDP. As part of the EGO complex, Gtr1 and Gtr2 are anchored to the vacuole via Ego1, Ego2, and Ego3. Leucine promotes GTP loading of Gtr1, which depends on the GEF Vam6 or the moonlighting leucyl tRNA synthetase Cdc60. The trimeric SEACIT, the yeast GATOR1 ortholog, is a GAP for Gtr1 and is inhibited by the pentameric SEACAT, the yeast GATOR2 ortholog. The Lst4-Lst7 complex is a GAP for Gtr2 downstream of glutamine. Glutamine also mediates sustained TORC1 activity independently of the Gtr proteins. Arrows and bars represent activation and inhibition, respectively, of the downstream protein.
that the yeast Ego1-Ego2-Ego3 ternary complex (EGO complex) is a structural ortholog of the RAGULATOR complex [32] (Figures 1 and 2 ). Ego1 contains potential myristoylation and palmitoylation sites at its N-terminus, like LAMTOR1, and deletion of EGO1 abrogates vacuolar localization of Ego2 and Ego3 [32, 45, 46] . An N-terminal region of Ego3 serves as a docking site for Gtr1-Gtr2 on the vacuole. However, it is unclear whether the EGO complex has GEF activity toward Gtr1. Binda et al. [39] identified Vam6 in a genome-wide screen as a poten-npg www.cell-research.com | Cell Research tial GEF for Gtr1 (Figure 2 ). Vam6 physically interacts with Gtr1, and stimulates GDP release from Gtr1 in vitro, indicating that Vam6 is indeed a GEF for Gtr1. VPS39 is the mammalian ortholog of yeast Vam6, but VPS39 does not interact with RAGA and has no effect on guanine nucleotide release from RAGB, suggesting that VPS39 is not the GEF for RAGA and RAGB in mammals [43] .
The identification of the lysosome as a platform for mTORC1 suggested that there might be other lysosomal components involved in the amino acid-sensing branch of mTORC1. An RNA interference screen targeting lysosomal proteins in Drosophila S2 cells revealed that knockdown of genes encoding the vacuolar H + -ATPase (V-ATPase) subunits inhibits amino acid-stimulated S6K phosphorylation [47] (Figure 1 ). V-ATPase is an ATP-driven proton pump that maintains cytoplasmic pH by acidifying the lysosomal lumen. It is a multi-subunit complex consisting of an ATP-hydrolytic domain (V1) and an integral membrane proton-pumping domain (V0) (reviewed in [48] ). Pharmacological inhibition of V-ATPase or knockdown of genes encoding V-ATPase components also prevents amino acid-induced mTORC1 activation [47] . Furthermore, Gtr1 interacts with V-ATPase in yeast, and deletion of a V-ATPase component (vma2∆) inhibits TORC1 activity [49] . These data suggest that the V-ATPase is an evolutionarily conserved upstream regulator of TORC1. Although it is not clear whether the V-ATPase in yeast is required for TORC1 activation in response to amino acids, this is likely the case since the growth defect of vma2∆ cells is partially reversed by overexpression of Gtr1-GTP [49] .
How does V-ATPase promote mTORC1 activity? Biochemical analysis demonstrated that the RAGULA-TOR complex physically interacts with V-ATPase via LAMTOR1-V0 domain and LAMTOR2-V1 domain associations. The interaction between LAMTOR2 and the V1 domain, but not the LAMTOR1-V0 interaction, is sensitive to amino acids, i.e., amino acids weaken the interaction [47] . The physiological significance of this regulated interaction is unknown. In cells expressing a constitutively active form of RAGA or RAGB, mTORC1 is constitutively localized to the lysosome and is active even in the presence of V-ATPase inhibitors [47] . Thus, V-ATPase appears to act upstream of the RAG and RAGULATOR complexes and is required for lysosomal translocation of mTORC1 in response to amino acids via an unknown mechanism.
GATOR1, a GAP for RAGA/B
Two studies independently identified the GAPs for yeast Gtr1 and mammalian RAGA/B [50, 51] . In yeast, Iml1 forms a complex with Npr2 and Npr3 (a complex termed SEACIT, Seh1-associated complex subcomplex inhibiting TORC1 signaling) [52] [53] [54] . Iml1 in the SEAC-IT complex acts as a GAP toward Gtr1. Mutation of the GAP domain in Iml1 abolishes the GAP activity and ability to inhibit TORC1 [51] (Figure 2 ). The mammalian orthologs of SEACIT components, DEP domain containing 5 (DEPDC5), nitrogen permease regulator 2-like protein (NPRL2), and NPRL3, form a complex named GATOR1 that has GAP activity toward RAGA/B [50] ( Figure 1 ). mTORC1 is insensitive to amino acid withdrawal in GATOR1-depleted cells [50] . The GAP domain in yeast Iml1 is conserved in mammalian DEPDC5 [51] . Expression of human DEPDC5 in iml1∆ cells suppressed TORC1 activity, suggesting that DEPDC5 in GATOR1 is the GAP catalytic subunit toward RAGA/B-GTP [51] .
The yeast Seh1-associated complex subcomplex activating TORC1 (SEACAT), consisting of Sec13, Seh1, Sea2, Sea3, and Sea4, and the mammalian GATOR2, a complex consisting of SEC13, SEH1L, WDR24, WDR59, and MIOS, are interactors and negative regulators of SEACIT and GATOR1, respectively [54] . The reader is referred to Dokudovskaya and Rout [55] for more details on SEA and GATOR complexes.
SESTRIN
SESTRIN (SESN)1/2/3 are stress-inducible proteins that maintain metabolic homeostasis and suppress obesity-and age-mediated pathologies (reviewed in [56] ). It was previously reported that SESNs inhibit mTORC1 through activation of AMPK and the TSC complex, causing inhibition of cell growth [57, 58] . More recently, four independent studies demonstrated that SESNs inhibit mTORC1 independently of the AMPK-TSC complex axis [59] [60] [61] [62] (Figure 1 ). All four studies showed that SESNs, especially SESN2, inhibit amino acid-induced lysosomal localization and activation of mTORC1. However, two distinct mechanisms are described. Chantranupong et al. [60] , Parmigiani et al. [61] , and Kim et al. [62] reported that SESNs bind and inhibit GATOR2. These studies also found that the interaction between SESNs and GATOR2 is strengthened upon amino acid starvation. Two of the studies showed that SESN overexpression does not affect the GATOR2-GATOR1 interaction or GAP activity of GATOR1 toward RAGA/B [60, 61] . However, Kim et al. [62] demonstrated that SESN2 overexpression indeed releases GATOR1 from GATOR2-mediated inhibition, thus allowing GATOR1 to stimulate hydrolysis of GTP in RAGB. Kim et al. speculated that this discrepancy could be due to the extent of SESN overexpression relative to expression of the GATOR complexes. Intriguingly, Kim et al. demonstrated that SESN2 overexpression or ER stress, a known inducer of SESN expression, induces dissociation of endogenous GATOR2 from endongenous GATOR1 in mouse liver. This finding suggests that SESN2 acts to release GATOR1 from GATOR2 in a physiologically relevant manner. Contrary to a mechanism in which SESNs act on GATOR2, Peng et al. [59] suggested that SESN is a guanine nucleotide dissociation inhibitor (GDI) for RAGA and RAGB. Peng et al. further showed that SESNs interact with the RAGs and prevent GDP dissociation in RAGA and B, but not in RAGC or RAGD. Introduction of point mutations in the conserved GDI motif of SESN2 abolished its GDI activity toward RAGB and the ability of SESN2 to inhibit mTORC1 lysosomal localization and activity, supporting their hypothesis that SESNs act upstream of mTORC1 as GDIs for RAGA or RAGB. Peng et al. [59] also showed that overexpressed SESN2 partially co-localizes with RAGs, presumably on the lysosome, while Parmigiani et al. [61] and Kim et al. [62] reported that overexpressed SESN2 does not localize to the lysosome. The reason for this discrepancy is not known. Investigation of endogenous SESN localization may clarify whether SESNs are localized to the lysosome to act as GDIs. The nature of the selectivity of GDI function for RAGA/B is unclear, but the study of Peng et al. speculated that negatively charged aspartic acid in the switch2 motifs of RAGA and RAGB interacts with positively charged amino acid sequences in the GDI motif of SESNs. Structural information on SESNs and the RAG heterodimer will provide further insight regarding the selectivity of SESN GDI activity. How do amino acids regulate the GDI activity of SESNs? Peng et al. speculated that amino acid stimulation promotes dissociation of SESNs from RAGA and RAGB through an unknown GDI displacement factor (GDF). As the authors further speculated, RAGULATOR may function as the GDF since GEFs can function as a GDF for their target GTPases. Alternatively, given the fact that GATOR2 interacts with SESNs in an amino acid-sensitive manner, GATOR2 might inhibit GDI activity of SESNs, a function distinct from negative regulation of GATOR1 [60] [61] [62] . At this point, both models, in which SESNs act as a negative regulator of GATOR2 and as a GDI for RAGA/B, are possible.
It is unknown whether a GDI for Gtr1 exists in yeast. Based on primary amino acid sequence, SESN orthologs are not found in yeast despite the extensive conservation of the TORC1 amino acid-sensing pathway. It is possible that SESNs are metazoan-specific regulators of mTORC1 in response to amino acids. Alternatively, like RAGULA-TOR and the EGO complex, a yet to be identified functional ortholog(s) may exist in yeast.
RNF152 and SKP2, E3 ubiquitin ligases for RAGA
It was recently reported that RAGA is also regulated by lysine 63-linked ubiquitination. Two independent studies demonstrated that RAGA ubiquitination promotes its binding to GATOR1, leading to inactivation of RAGA [63, 64] . Deng et al. [64] identified RNF152 as the E3 ubiquitin ligase that mediates ubiquitination of RAGA at lysine 142, 220, 230, and 244, while Jin et al. [63] found that another E3 ubiquitin ligase, SKP2, mediates ubiquitination of RAGA at lysine 15. Each study showed that the described ubiquitination increases interaction between RAGA and GATOR1, and overexpression of a RAGA ubiquitination-deficient mutant (K142R, K220R, K230R, K244R, or K15R) reduces RAGA-GATOR1 interaction, and thus increases mTORC1 activity. How are RNF152 and SKP2 regulated in response to amino acids? Deng et al. [64] showed that amino acid starvation increases RNF152 interaction with RAGA and RAGA ubiquitination. However, RNF152 preferentially binds to the already inactive RAGA-GDP, suggesting that RNF152-mediated ubiquitination is not the primary mechanism of RAGA inactivation by GATOR1. Jin et al. [63] surprisingly found that amino acids promote SKP2-mediated RAGA interaction with GATOR1. This observation is inconsistent with a previous study showing that amino acid starvation increases the interaction between GATOR1 and RAGA [50] . SKP2 recruitment to RAGA upon amino acid stimulation is dependent on mTORC1 activity since rapamycin prevents SKP2 recruitment as well as interaction between RAGA and GATOR1 [63] . Jin et al. proposed that SKP2-mediated RAGA ubiquitination is a negative feedback mechanism to prevent mTORC1 hyperactivation upon amino acid stimulation. Both studies showed that MEFs from RNF152-or SKP2-knockout mice have increased mTORC1 activity, presumably due to increased RAGA-GTP levels [63, 64] . Curiously, both RNF152 and SKP2 knockout mice are viable [64, 65] in contrast to neonatal lethality conferred by RAGA-GTP knockin [66] or SESN knockout [59] (see below). This may suggest that RNF152 and SKP2 have a small role in mTORC1 physiology, or their function may be relevant only in specific physiological contexts.
Folliculin (FLCN), a GAP for RAGC and RAGD
Compared to RAGA/B, regulation of the guanine nucleotide status in RAGC/D is less characterized. A GEF for RAGC/D or Gtr2 has yet to be identified. FLCN has been linked to the TOR pathway in different organisms including yeast [67, 68] , fly [69] , mouse [70] [71] [72] , and human [70, 72, 73] . Two recent studies showed that FLCN in complex with FLCN-interacting protein (FNIP) promotes mTORC1 lysosomal translocation and activity in npg www.cell-research.com | Cell Research response to amino acids [74, 75] (Figure 1) . FLCN localizes to the lysosome upon amino acid starvation and only when RAGA/B is inactive. Upon amino acid stimulation, RAGA or RAGB is loaded with GTP, liberating FLCN from the lysosome. Tsun et al. [75] further demonstrated that FLCN is a GAP for RAGC and RAGD to promote the active conformation of RAGC and RAGD. Since FLCN is already localized to the lysosome in the absence of amino acids, it requires amino acids only to stimulate its GAP activity. Interestingly, FLCN is well conserved from yeast to human, and deletion of the yeast FLCN ortholog Lst7 is synthetically lethal with mutation of the sec13 gene [76] encoding a component of SEACAT/ GATOR2 [54] . An explanation for the synthetic lethality could be that double mutation of SEC13 and LST7 completely abolishes amino acid input into TORC1. Indeed, a recent study showed that Lst7 forms a complex with Lst4, a yeast ortholog of FNIP, and is a GAP for Gtr2 [77] . Like in mammals, the Lst4-Lst7 complex in yeast localizes to the vacuole upon amino acid starvation. Amino acids, especially glutamine, promote binding of the Lst4-Lst7 complex to Gtr2, hydrolysis of GTP in Gtr2, and thereby TORC1 activity. Active TORC1 then releases the Lst4-Lst7 complex from the vacuole to attenuate GAP function of the Lst4-Lst7 complex, thus providing a negative feedback mechanism to tightly control TORC1 activity [77] .
What and where is the amino acid sensor?
This is a long-standing question in the TOR field. What properties should an amino acid sensor have? First, it should bind directly to amino acids at a physiologically relevant concentration. Second, amino acid binding should affect its function. Third, the sensor should transmit the signal of amino acid availability to TORC1. Sensors have been proposed to exist in the lysosome, mitochondria, and cytoplasm. Zoncu et al. [47] suggested that amino acids are obligatorily sensed in the lumen of the lysosome and signal to the RAGs in a V-ATPase-dependent manner, a so-called "inside-out" mechanism. Amino acids promote mTORC1 binding to RAGs on isolated lysosomes in vitro, and inhibition of the V-ATPase prevents mTORC1 binding. In addition, pumping amino acids out of the lysosomal lumen by overexpression of the proton/ amino acid transporter 1 (PAT1) prevents amino acid-induced binding of mTORC1 to isolated lysosomes [47] . According to their lysosome-centric "inside-out" model, Zoncu et al. suggested that amino acids, including leucine, must accumulate in the lysosomal lumen to activate mTORC1.
How are amino acids transported into the lysosomal lumen and sensed? A recent study demonstrated that leucine flux into the lysosomal lumen is mediated by solute carrier (SLC) family proteins SLC7A5-SLC3A2 [78] that were previously shown to be plasma membrane antiporters that transport leucine into the cell in exchange for glutamine [79] (Figure 1 ). This recent study also found that overexpression of lysosomal-associated transmembrane protein 4b (LAPTM4b) promotes lysosomal localization of SLC7A5-SLC3A2 and thus leucine flux into the lysosome. Three other independent studies suggested that another SLC family member found in the lysosomal membrane, SLC38A9, is an amino acid sensor for mTORC1 [80] [81] [82] . Biochemical analysis revealed that the transmembrane protein SLC38A9 is part of a RAG-RAGULATOR supercomplex. All three studies showed that SLC38A9 is necessary for amino acids to activate mTORC1 in a RAG-and RAGULATOR-dependent manner. However, V-ATPase is dispensable for SLC38A9-mediated activation of mTORC1, suggesting that SLC38A9 and V-ATPase act in parallel upstream of the RAG-RAGULATOR complex. The interaction between SLC38A9 and the RAG-RAGULATOR complex is strengthened upon amino acid starvation, consistent with the observation that SLC38A9 preferentially binds the inactive form of RAG proteins. Furthermore, in vitro amino acid transport assays using liposomes reconstituted with SLC38A9 oriented with its N terminus facing out, equivalent to its orientation in the lysosomal membrane, suggest that SLC38A9 transports glutamine and arginine, but not leucine, into the lysosome [80, 81] . Rebsamen et al. [81] further showed that SLC38A9 pumps glutamine out of liposomes with a rate greater than its glutamine influx rate. However, the transport rate of SLC38A9 is relatively low compared with other amino acid transporters. Interestingly, overexpression of an N-terminal cytoplasmic tail of SLC38A9 (minimum amino acids 1-112) causes mTORC1 to be insensitive to amino acid starvation, indicating that the cytoplasmic tail of SLC38A9 is sufficient to activate mTORC1. This gain-of-function phenotype conferred by a soluble cytoplasmic tail also suggests that amino acid transport activity is not required for mTORC1 activation. Altogether, these studies propose that SLC38A9 is a lysosomal amino acid sensor upstream of mTORC1. Consistent with the in vitro data, arginine, but not leucine, failed to activate mTORC1 in the absence of SLC38A9, suggesting that SLC38A9 is an arginine sensor [80] . It is still unclear whether arginine is sensed in the lysosomal lumen or the cytoplasm. Although SLC38A9 also transports glutamine, the ability of SLC38A9 to signal glutamine availability to mTORC1 in cells has not been tested. The observation that over-expression of a dominant-negative RAG heterodimer blocks mTORC1 activation by SLC38A9 overexpression suggests that SLC38A9 acts upstream of RAG [80] . Curiously, Rebsamen et al. [81] and Jung et al. [82] found that mTORC1 remains bound to the lysosome in SLC38A9 knockdown cells, suggesting that SLC38A9 is not required for RAG-mediated mTORC1 recruitment to the lysosome. SLC38A9 homologs in yeast comprise seven vacuolar amino acid transporters (Avts). Of these Avt proteins, Avt1, 2, and 3 contain an N-terminal region similar to the N terminus of SLC38A9. It would be of interest to determine whether the yeast homologs of SLC38A9 play an evolutionarily conserved role in TORC1 signaling. Yet another lysosomal solute carrier protein, SLC15A4, has been linked to mTORC1 activity in B cells [83] . SLC15A4-knockout B cells accumulate histidine in the lysosome and display increased lysosomal pH, decreased V-ATPase activity, and reduced mTORC1 activity. Although this study showed that SLC15A4 and mTORC1 colocalize to the lysosome, the role of SLC15A4 in mTORC1 signaling remains to be clarified.
In addition to or contrary to the lysosome-centric "inside-out" model of amino acid sensing, recent evidence suggests that amino acids, especially leucine and glutamine, are sensed outside the lysosome. Han et al. [84] reported that the cytoplasmic protein leucyl-tRNA synthetase (LRS) senses leucine to promote mTORC1 lysosomal localization and activity. This study further showed LRS acts as a GAP specifically for RAGD. However, the role of LRS as a GAP has been questioned [75] . Tsun et al. [75] reported that LRS does not have GAP activity. The reason for this discrepancy is not known. Cdc60, the yeast ortholog of LRS, physically interacts with Gtr1 and is necessary and sufficient to activate TORC1 in response to leucine stimulation [85] (Figure 2 ). Genetic analysis also suggests that Cdc60 acts upstream of Gtr1. The studies of Han et al. [84] and Bonfils et al. [85] are consistent with the notion that LRS/Cdc60 is a cytoplasmic leucine sensor upstream of TORC1. Interestingly, Wolfson et al. [86] very recently demonstrated that leucine binds the cytoplasmic protein SESN2 and thereby inhibits SESN2-GATOR2 interaction. Thus, SESN2 is almost certainly a cytoplasmic leucine sensor [86] , although it remains to be shown whether leucine-mediated inhibition of the SENS2-GATOR2 interaction impinges on GATOR1 and RAGs.
Duran et al. [87, 88] suggested that glutaminolysis, the double deamination of glutamine catalyzed by glutaminase (GLS) and glutamate dehydrogenase (GDH) to produce α-ketoglutarate (αKG), activates RAGmTORC1 through prolyl hydroxylase (PHD). αKG is a co-factor for PHD. Leucine binds and activates GDH, the enzyme that catalyzes the second deamination step in glutaminolysis, leading to αKG production. Since glutaminolysis takes place in mitochondria, this mechanism is distinct from lysosomal sensing (Figure 1) . The glutaminolysis model provides a sensing mechanism for the activation of mTORC1 by leucine and glutamine.
RAG-independent activation of mTORC1 in response to nutrients
Unlike deletion of TORC1 components, deletion of GTR1 and GTR2 is not lethal in yeast. In mammals, although whole-body RAGA knockout in mice is embryonic lethal [89] , RAGA-knockout MEFs and RAGA-and B-deficient cardiomyocytes sustain mTORC1 activity (see below) [90] . These observations hint at the existence of alternative or compensatory mechanism of TORC1 activation independent of RAG/Gtr. Stracka et al. [91] recently showed that glutamine, a nitrogen source and the major nutrient input for TORC1 in yeast, activates TORC1 in the absence Gtr1 or Vam6. Consistent with this yeast study, glutamine promotes lysosomal translocation and activation of mTORC1 in RAGA-and RAGB-deficient mammalian cells [92] , suggesting that RAG/Gtr-independent activation of TORC1 by glutamine may be an evolutionarily conserved mechanism. In addition, Jewell et al. [92] demonstrated that RAGULATOR, but not V-ATPase, is dispensable for glutamine-mediated mTORC1 lysosomal translocation and activation. In this case, the small GTPase ADP-ribosylation factor 1 (ARF1) appears to substitute for RAG in mTORC1 activation (Figure 1 ). The molecular mechanism by which ARF1 senses glutamine and controls mTORC1 requires further investigation.
RAG-independent activation of mTORC1 was further demonstrated by Thomas et al. [93] . This study identified Ypt1 in yeast and RAB1A in mammals as Gtr-and RAG-independent, respectively, regulators of TORC1. Mechanistically, amino acids promote GTP loading of RAB1A, which in turn stimulates RHEB-mTORC1 interaction on the Golgi (Figure 1 ). How and where amino acid availability is transduced to RAB1A need further investigation.
Amino acid sensing branch of mTORC1 signaling in mice
Efeyan et al. [66] generated and characterized RA-GA-Q66L knock-in mice in which RAGA is preferentially loaded with GTP (RAGA-GTP mice). Unlike TSC1-or TSC2-knockout mice which die at embryonic day npg www.cell-research.com | Cell Research 9.5-13.5 [15, 94, 95] , RAGA-GTP mice exhibit normal embryonic development and are born with the expected Mendelian ratio [66] . However, these mice are unable to survive beyond postnatal day 1. Autophagy supplies amino acids for hepatic gluconeogenesis to prevent hypoglycemia in newborn mice. Constitutive activation of mTORC1 in RAGA-GTP mice inhibits autophagy and thereby prevents supply of gluconeogenic amino acids in the liver. This leads to hypoglycemia, faster breakdown of hepatic glycogen, energetic collapse, and ultimately neonatal death. Similar neonatal lethality was observed in mice with hyperactive mTORC1 due to deletion of all three SESNs [59] . These studies suggest that neonatal inhibition of RAG-mTORC1 signaling and subsequent activation of autophagy are critical for survival.
Although RAGA-GTP mice show no abnormalities during embryonic development, RAGA knockout mice display developmental aberrations and die at embryonic day 10.5 [89] . Compared with RAGA, RAGB is less expressed in most organs, and is dispensable for normal development and mTORC1 activity at least in brain and liver. RAGB might compensate for embryonic loss of RAGA since RAGB expression is mildly upregulated in RAGA-knockout mice, and RAGA and RAGB double knockout embryos die slightly earlier than RAGA-knockout embryos. Indeed, liver-specific RAGA loss is partially compensated by upregulation of RAGB expression, and loss of RAGB in RAGA-deficient hepatocytes further reduces mTORC1 signaling. Liver-specific RA-GA-knockout mice show reduced mTORC1 activity and, most likely due to loss of the negative feedback loop, higher AKT activity. Higher AKT activity is reflected in increased inhibitory phosphorylation of the transcription factor FOXO and decreased FOXO-mediated transcription of the phosphoenolpyruvate carboxykinase (PEP-CK), glucose-6-phosphatase (G6P), and glucokinase genes. Reduced expression of these gluconeogenic genes may explain the mild reduction in blood glucose levels observed in the liver-specific RAGA-knockout mice. Like knockout in the embryo, acute knockout of RAGA in adult mice is lethal. Within 2-3 weeks after induction of RAGA knockout, mice die due to intestinal atrophy. Deletion of RAGA in adult mice also expands monocytes in the bone marrow and spleen. The relationship among lethality, intestinal atrophy, and monocytosis remains to be determined.
Kim et al. [90] generated cardiomyocyte-specific RAGA and RAGB double knockout mice, which exhibited cardiac hypertrophy and cardiomyopathy, leading to heart dysfunction. Unlike whole-body knockout [89] , single knockout of RAGA or RAGB in cardiomyocytes did not confer a heart defect, suggesting that RAGA and RAGB have functionally redundant roles in cardiomyocytes. Surprisingly, mTORC1 activity was not impaired in the cardiomyocyte-specific RAGA/B double knockout mice. The authors speculate that upregulated PI3K-Akt signaling might compensate for loss of RAG in the activation of mTORC1 [90] .
Unlike cultured cells, cells in their natural setting never experience complete depletion of amino acids. This raises the question of whether amino acid-induced lysosomal translocation of mTORC1 happens in vivo. Recently, Chen et al. [96] demonstrated that acute amino acid infusion promotes mTORC1 lysosomal translocation and activation in the kidney. Moreover, chronic amino acid infusion increases protein synthesis and kidney size, presumably due to hyperactivation of mTORC1. It would be of particular interest to investigate whether amino acid-induced mTORC1 translocation to lysosomes in vivo is dependent on RAGs, RAGULATOR, or V-ATPase, and whether mTORC1 lysosomal translocation happens in other tissues such as liver and muscle where mTORC1 plays a critical role in whole-body metabolism [6, [97] [98] [99] [100] [101] [102] [103] [104] .
Human diseases associated with defects in amino acid sensing
In contrast to well-characterized tumorigenic mutations in PI3KCA, TSC1, and TSC2 that affect the growth factor signaling pathway, mutations affecting amino acid sensing were recognized only recently. Before identification of RAGULATOR as an upstream regulator of mTORC1, RAGULATOR component LAMTOR2, originally known as p14, was linked to a primary human immunodeficiency syndrome characterized by short stature, hypopigmented skin, coarse facial features and recurrent bronchopulmonary infection by Streptococcus pneumoniae [105] . Genetic linkage studies and genome-wide transcriptional profiling analyses of the human primary immunodeficiency syndrome identified a homozygous point mutation in the 3′ untranslated region (UTR) of LAMTOR2/p14. It was then shown that the 3′UTR mutation indeed reduces stability of the mRNA and thus decreases protein expression. LAMTOR2/p14 was previously characterized as a positive regulator of a mitogen-activated protein kinase (MAPK) pathway [106] . It is not clear whether the disease is due to reduced MAPK or mTORC1 activity. However, cells derived from patients have reduced mTORC1 activity [38] , and this defect appears to be more severe than the defect in MAPK signaling [105] . Since TORC1 controls cell and organism size, and rapamycin is immunosuppressive, it seems likely that reduced mTORC1 activity accounts for the disease phenotype.
Mutation of NPRL2 or DEPDC5, genes encoding GATOR1 components, has been linked to lung, breast, ovarian, kidney, liver and brain cancers [50, [107] [108] [109] [110] [111] [112] [113] . Indeed, cancer cells harboring homozygous loss of function mutations in GATOR1 components have elevated mTORC1 activity that is insensitive to amino acid starvation [50] . Introduction of a functional GATOR1 component in these cells restored mTORC1 sensitivity to amino acid depletion and reduced cell proliferation. These findings suggest that GATOR1 is a tumor suppressor complex upstream of mTORC1. Two independent exome-sequencing analyses of familial focal epilepsy identified loss-of-function mutations in DEPDC5 [114, 115] , suggesting that hyperactive mTORC1 may cause epilepsy and mTORC1 inhibitors may be used to treat this disorder.
Birt-Hogg-Dube (BHD) syndrome is a rare disease characterized by multiple benign skin and hair follicle tumors. Patients with BHD syndrome also have increased risk of developing cysts in the lung and high incidence of kidney tumors. Loss-of-function mutations in the FLCN gene cause the BHD syndrome, and FLCN is thus considered a tumor suppressor [116] . Indeed, kidney-specific knockout of FLCN causes upregulation of MAPK and PI3K-Akt-mTOR signaling, which may explain the kidney hyperplasia observed in FLCN-knockout mice [72, 117] . The renal hyperplasia was at least in part due to upregulation of mTORC1 signaling since rapamycin treatment reduced kidney size and extended lifespan. Consistent with the mouse study, renal tumors from BHD patients also showed upregulation of mTORC1 activity [72, 117] . However, it is counterintuitive that FLCN, a positive regulator of mTORC1, is a tumor suppressor. Future studies are required to clarify the apparent discrepancy that FLCN behaves like an oncogene in cultured cells (see section on FLCN above) but is a tumor suppressor in the BHD syndrome.
RAB1A overexpression is frequently observed in tongue squamous carcinomas, colorectal cancer, and hepatocellular carcinoma, and correlates with hyperactive mTORC1 signaling and poor prognosis [93, 118] . Cell proliferation assays in vitro and xenograft studies in vivo further demonstrated that RAB1A overexpression promotes oncogenic growth of cancer cells in a rapamycin-sensitive manner.
Closing remarks and future directions
The finding that RAG proteins regulate TORC1 in response to nutrients is a milestone in TOR research. Follow-up studies to elucidate regulators of the RAG proteins have expanded the list of molecules involved in amino acid sensing, and studies in mice have provided important insight into the physiology and pathophysiology of amino acid sensing. However, several questions remain.
How are amino acids sensed?
The answer to this question is more complex than previously expected. Increasing evidence suggests that different amino acids are sensed at distinct locations in the cell and signal to mTORC1 in RAG-dependent and -independent manners. Investigation of upstrem regulator of the FNIP-FLCN complex may lead to yet unknown amino acid sensors. For RAG-independent sensing, studying upstream regulators of ARF1 may provide a glutamine sensor. It would also be of interest to examine whether glutamine signals to mTORC1 via a common sensor in RAG-dependent and -independent manners. Intriguingly, loss of TORC1 function in yeast is lethal whereas deletion of both GTR1 and GTR2 (gtr1∆ gtr2∆ cells) is not lethal [119] . Furthermore, glutamine signals to TORC1 in a Gtr1-independent manner. Thus, a yeast synthetic lethal screen in grt1∆gtr2∆ cells might identify a mechanism by which cells sense and transduce glutamine availability to TORC1.
How important is amino acid sensing in the whole animal?
Studies on amino acid signaling in mice have provided unexpected insight. For example, acute deletion of RAGA in adult mice causes monocytosis [89] , revealing a previously unrecognized role of mTORC1 in this disease characterized, curiously, by monocyte proliferation. Follow-up studies using cell type-specific RAGA-knockout mice are needed to elucidate the role of amino acid signaling in monocyte function and presumably immunity.
Although amino acid infusion promotes mTORC1 lysosomal translocation in the kidney, further studies are required to demonstrate the extent of this form of regulation in the whole animal. As discussed above, amino acids are rarely depleted in the animal. What is the physiological amino acid concentration that elicits lysosomal translocation of mTORC1 and how often is this achieved? To this end, amino acid levels in vivo should be examined by metabolomic analysis and correlated with mTORC1 lysosomal translocation. Experiments such as amino acid infusion in cell type-specific RAG-knockout mice will indicate whether findings in vitro apply in vivo.
Recent findings revealed that the amino acid signaling pathway is clinically relevant. Mutations in pathway components are linked to human diseases. Furthermore, npg www.cell-research.com | Cell Research cancer cells harboring mutations in components of GA-TOR1 or overexpressing RAB1A are hypersensitive to mTORC1 inhibition [50, 93] . Thus, alterations in the amino acid signaling pathway could serve as biomarkers to predict efficacy of mTORC1 inhibitors. Further analysis of mice carrying mutations in disease-causing genes such as NPRL2 or DEPDC5 will provide more insight into the role of amino acid sensing in disease. Finally, examination of patients in which mTORC1 activity is deregulated may provide more information on amino acid sensing in human physiology.
